Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNXNASDAQ:GOSSNASDAQ:HURANASDAQ:MURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$1.88-1.6%$2.18$1.29▼$7.85$206.26M1.241.82 million shs865,808 shsGOSSGossamer Bio$0.96-2.1%$1.11$0.50▼$1.55$217.75M1.881.58 million shs2.46 million shsHURATuHURA Biosciences$4.10-3.1%$3.26$1.80▼$7.93$179.09M0.8264,195 shs149,056 shsMURAMural Oncology$2.60-1.5%$2.71$0.95▼$4.74$44.79M5.281.29 million shs434,657 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon+3.80%+30.82%-22.67%-53.75%-57.08%GOSSGossamer Bio+9.43%+16.57%-23.50%+5.29%+38.25%HURATuHURA Biosciences+0.71%+1.93%+16.21%-2.98%+422,999,900.00%MURAMural Oncology-4.69%-2.22%+79.59%-33.16%-26.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANNXAnnexon2.6745 of 5 stars3.53.00.00.03.11.70.6GOSSGossamer Bio3.7762 of 5 stars3.52.00.04.72.71.70.0HURATuHURA BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AMURAMural Oncology2.2325 of 5 stars3.33.00.00.00.91.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 3.00Buy$18.67892.91% UpsideGOSSGossamer Bio 3.00Buy$7.50682.64% UpsideHURATuHURA Biosciences 3.25Buy$12.67208.94% UpsideMURAMural Oncology 2.60Moderate Buy$13.00400.00% UpsideCurrent Analyst Ratings BreakdownLatest MURA, GOSS, ANNX, and HURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025GOSSGossamer BioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.004/3/2025HURATuHURA BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$13.00 ➝ $12.003/26/2025MURAMural OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $6.003/25/2025MURAMural OncologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight3/25/2025MURAMural OncologyRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$18.003/25/2025MURAMural OncologyJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold3/18/2025GOSSGossamer BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/14/2025GOSSGossamer BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$4.00 ➝ $4.003/12/2025MURAMural OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.003/4/2025ANNXAnnexonNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.003/3/2025HURATuHURA BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$13.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$3.20 per shareN/AGOSSGossamer Bio$114.70M1.90N/AN/A$0.28 per share3.42HURATuHURA BiosciencesN/AN/AN/AN/A($4.11) per shareN/AMURAMural OncologyN/AN/AN/AN/A$15.81 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$134.24M-$1.02N/AN/AN/AN/A-38.99%-33.90%5/12/2025 (Estimated)GOSSGossamer Bio-$179.82M-$0.26N/AN/AN/AN/A-127.28%-22.12%5/6/2025 (Estimated)HURATuHURA Biosciences-$8.32MN/A0.00∞N/AN/AN/A-152.88%5/13/2025 (Estimated)MURAMural Oncology-$207.45M-$7.58N/AN/AN/AN/A-70.10%-61.30%5/13/2025 (Estimated)Latest MURA, GOSS, ANNX, and HURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025N/AHURATuHURA Biosciences-$0.14N/AN/AN/AN/AN/A5/13/2025N/AMURAMural Oncology-$1.68N/AN/AN/AN/AN/A5/12/2025Q1 2025ANNXAnnexon-$0.30N/AN/AN/AN/AN/A5/6/2025Q1 2025GOSSGossamer Bio-$0.19N/AN/AN/A$3.95 millionN/A3/18/2025Q4 2024GOSSGossamer Bio-$0.15-$0.15N/A-$0.15$7.02 million$9.38 million3/11/2025Q4MURAMural Oncology-$1.96-$2.01-$0.05-$2.01N/AN/A3/3/2025Q4 2024ANNXAnnexon-$0.28-$0.33-$0.05-$0.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/AGOSSGossamer BioN/AN/AN/AN/AN/AHURATuHURA BiosciencesN/AN/AN/AN/AN/AMURAMural OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A17.1717.18GOSSGossamer Bio3.646.746.74HURATuHURA BiosciencesN/A1.541.54MURAMural OncologyN/A7.387.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/AGOSSGossamer Bio81.23%HURATuHURA Biosciences0.62%MURAMural Oncology80.21%Insider OwnershipCompanyInsider OwnershipANNXAnnexon12.67%GOSSGossamer Bio5.00%HURATuHURA Biosciences0.20%MURAMural Oncology0.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.71 million93.09 millionOptionableGOSSGossamer Bio180227.22 million215.27 millionOptionableHURATuHURA BiosciencesN/A43.68 million42.20 millionN/AMURAMural Oncology11917.23 million17.01 millionOptionableMURA, GOSS, ANNX, and HURA HeadlinesRecent News About These CompaniesParkwood Master Fund Ltd - Form 8.3 - Mural Oncology PlcApril 24 at 9:30 PM | uk.finance.yahoo.comForm 8.3 - Mural Oncology plcApril 22 at 11:17 AM | finance.yahoo.comBoston-area cancer research lab to cease drug trials, lay off 117April 22 at 1:15 AM | msn.comMass. biotech company cuts 90% of workforceApril 17, 2025 | msn.comForm 8.3 - The Vanguard Group, Inc.: Mural Oncology plcApril 17, 2025 | markets.businessinsider.comMural Oncology to discontinue nemvaleukin development, reduce staff by 90%April 16, 2025 | markets.businessinsider.comMURA Soars as it Explores Strategic Options Post Cancer Study FailuresApril 16, 2025 | zacks.comStrategic rethink as second Mural trial hits a wallApril 16, 2025 | thepharmaletter.comMural shuts down lead programme and slashes 90% of staffApril 16, 2025 | finance.yahoo.comBiotech Stock Mural Oncology (Nasdaq: MURA) Makes NASDAQ Top Gainer List on NewsApril 15, 2025 | investorideas.comBiotech Company Sees Stock Boost Following Major Strategy ShiftApril 15, 2025 | msn.comMural Oncology to Explore Options, Cut 90% of WorkforceApril 15, 2025 | marketwatch.comMural Oncology cuts 90% of staff, pulls plug on cancer drugApril 15, 2025 | bizjournals.comMural Oncology Shares Surge As Company Explores Strategic Alternatives: What's Going On?April 15, 2025 | benzinga.comMural risks going to the wall as IL-2 flop triggers 90% staff reduction, hunt for strategic alternativesApril 15, 2025 | fiercebiotech.comMural Oncology Announces Plans to Explore Strategic AlternativesApril 15, 2025 | globenewswire.comMural Oncology plc Ordinary SharesApril 12, 2025 | fxempire.comDevelopment of Nemvaleukin for Platinum-Resistant Ovarian Cancer HaltedApril 3, 2025 | curetoday.comCity of Indio creates new mural in honor of young local who battled cancerApril 2, 2025 | kesq.comMural Oncology: Phase 3 Clinical Trial Setback Undermines Company's Future ProspectsMarch 28, 2025 | seekingalpha.comMural Oncology (NASDAQ:MURA) Receives Hold Rating from Jones TradingMarch 26, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMURA, GOSS, ANNX, and HURA Company DescriptionsAnnexon NASDAQ:ANNX$1.88 -0.03 (-1.57%) Closing price 04:00 PM EasternExtended Trading$1.85 -0.03 (-1.81%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Gossamer Bio NASDAQ:GOSS$0.96 -0.02 (-2.13%) Closing price 04:00 PM EasternExtended Trading$0.96 0.00 (-0.03%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.TuHURA Biosciences NASDAQ:HURA$4.10 -0.13 (-3.07%) Closing price 04:00 PM EasternExtended Trading$4.07 -0.03 (-0.73%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.Mural Oncology NASDAQ:MURA$2.60 -0.04 (-1.52%) Closing price 04:00 PM EasternExtended Trading$2.64 +0.03 (+1.35%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
